Johnson & Johnson's results for Q3 2026 come from the company's own earnings release, filed with the SEC on 2026-10-13. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP) | $25,399 million (+5.9% vs a year earlier) |
| Diluted EPS (GAAP) | $0.09 |
| Adjusted per-share figure (company's non-GAAP measure; FFO/AFFO for REITs) | $2.59 |
| Full-year guidance | Raised |
Guidance
J&J raised 2026 guidance: reported sales $101.0–101.4 billion (midpoint $101.2 billion) and adjusted EPS $11.05–11.15, up $0.06 at midpoint.
Why this label: 'raises 2026 guidance': reported sales midpoint $101.2B and adjusted EPS up $0.06 to $11.10 at the midpoint.
| Metric | Period | New | Prior (as stated in the release) |
|---|---|---|---|
| estimated reported sales | FY2026 | $101.0–101.4 billion (midpoint $101.2B) | $100.8–101.4 billion (midpoint $101.1B) |
| adjusted operational sales growth | FY2026 | 6.4%–6.8% | 6.2%–6.8% |
| operational sales | FY2026 | $100.5–100.9 billion | $100.3–100.9 billion |
| adjusted operational EPS (diluted) | FY2026 | $10.95–11.05 | $10.86–11.01 |
| adjusted EPS (diluted) | FY2026 | $11.05–11.15 (midpoint $11.10) | $10.96–11.11 (midpoint $11.04) |
From the release
Revenue: "Sales to customers · $ · 25,399 · 100.0 · $ · 23,993 · 100.0 · 5.9"
Earnings per share: "Net earnings per share (Diluted) · $ · 0.09 · $ · 2.12 · (95.8)"
estimated reported sales: "Estimated Reported Sales 3 / Mid-point Change vs. Prior Year / Mid-point · $101.0B – $101.4B / $101.2B 7.2% – 7.6% / 7.4% · $100.8B – $101.4B / $101.1B"
adjusted operational sales growth: "Adjusted Operational Sales 1,2 Change vs. Prior Year / Mid-point · 6.4% – 6.8% / 6.6% · 6.2% – 6.8% / 6.5%"
operational sales: "Operational Sales 2 / Mid-point Change vs. Prior Year / Mid-point · $100.5B – $100.9B /$100.7B 6.7% – 7.1% / 6.9% · $100.3B – $100.9B / $100.6B"
Quotes are copied from the filing; in table rows, cell borders are shown as “·”.
Key fact: Talc charge and deals cut Q3 EPS to $0.09; adjusted EPS guidance raised $0.06.
Source
Johnson & Johnson earnings release (SEC filing), accession 0000200406-26-000189, filed 2026-10-13.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.